Risk of Herpes Zoster Ophthalmicus Recurrence After Recombinant Zoster Vaccination
JAMA OphthalmologyImportanceThe recombinant zoster vaccine (RZV) is currently recommended for immunocompetent adults aged 50 years or older and immunocompromised adults aged 19 years or older and is effective in preventing herpes zoster ophthalmicus (HZO). However, questions about the safety of RZV in patients with a history of HZO remain.ObjectiveTo evaluate whether ...
Anushka, Walia +2 more
openaire +2 more sources
Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease
Digestive Diseases and Sciences, 2020Patients with inflammatory bowel disease (IBD) are at increased risk of developing herpes zoster. In October 2017, the FDA approved a two-dose adjuvanted, recombinant herpes zoster vaccine (RZV). There is a theoretical concern that vaccine adjuvants may cause flares in patients with immune-mediated diseases.
Venkata R. Satyam +6 more
openaire +2 more sources
Immunogenicity of Recombinant Zoster Vaccine: A Systematic Review, Meta-Analysis, and Meta-Regression [PDF]
VaccinesBackground: The adjuvanted recombinant zoster vaccine (RZV), consisting of varicella-zoster virus glycoprotein E (gE) and the AS01B adjuvant system, effectively prevents herpes zoster (HZ).
, Lorenzo G Mantovani, Silvio Tafuri
exaly +3 more sources
Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting
Annals of Internal MedicineA 2-dose series of recombinant zoster vaccine (RZV) was 97% effective against herpes zoster (HZ) in a pivotal clinical trial.To evaluate real-world effectiveness of RZV against HZ.Prospective cohort study.Four health care systems in the Vaccine Safety Datalink.Persons aged 50 years or older.The outcome was incident HZ defined by a diagnosis with an ...
Ousseny Zerbo +10 more
openaire +2 more sources
Herpes zoster after recombinant zoster vaccine: A first case report
The Journal of Allergy and Clinical Immunology: In Practice, 2020Laurie A, Housel, Bruce M, McClenathan
openaire +2 more sources
Acute psoriasis exacerbation by recombinant zoster vaccine: a case report
Acta Dermatovenerologica Alpina Pannonica et AdriaticaPsoriasis is a common chronic inflammatory skin disorder that primarily affects the skin, nails, and joints. Beyond its cutaneous manifestations, psoriasis is associated with several systemic comorbidities. Various factors can trigger or exacerbate psoriasis, including stress, infections, medications, and vaccinations.
openaire +2 more sources
Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure
Clinical Infectious Diseases, 2021Hector S Izurieta +2 more
exaly
Herpes Zoster and Varicella Encephalitis Following the Recombinant Zoster Vaccine
CutisMallory, Pane +2 more
openaire +2 more sources
Breakthrough herpes zoster risk after recombinant zoster vaccination
VaccineShih-Wei, Lai, Kuan-Fu, Liao
openaire +2 more sources